Engflag

Japrolox

Quick links to important sections

Japrolox

Japrolox_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Japrolox

Property Description
Active ingredient Loxoprofen Sodium (Anhydrous Loxoprofen Na)
Form Oral Tablet
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Pain relief, inflammation, and fever reduction
Origin Synthetic compound (Pro-drug)

Identity: Japrolox as a Non-Steroidal Anti-Inflammatory Drug (NSAID)

Japrolox is a prescription-only medicinal preparation that contains Loxoprofen Sodium, which is classified as a synthetic Non-Steroidal Anti-Inflammatory Drug (NSAID). This compound belongs to the propionic acid derivative subgroup. Loxoprofen is characterized by its role as a pro-drug. This distinct feature ensures the compound is pharmacologically inactive upon administration and only becomes therapeutically effective following rapid metabolism in the body. The medication's classification identifies it as a systemic agent used to address inflammatory processes internally.

Composition and Pharmaceutical Form of Loxoprofen

The active substance within the preparation is Loxoprofen Sodium, typically supplied as an oral tablet for systemic administration. The oral solid form facilitates the efficient absorption of the pro-drug compound via the digestive system. The active metabolite functions in managing acute inflammatory states by reducing prostaglandin production. For example, Loxoprofen is commonly used in therapeutic contexts requiring rapid relief from inflammatory pain.

General Purpose and Therapeutic Benefit

The general purpose of Loxoprofen Sodium is to provide efficient analgesia (pain relief), reduce inflammation, and lower fever. It achieves this by the active metabolite's ability to inhibit cyclooxygenase (COX) enzymes, thereby suppressing the synthesis of prostaglandins, which are the essential chemical mediators of inflammation and pain. By interrupting this chemical signaling pathway, the medicine helps alleviate discomfort and mitigate swelling associated with various inflammatory states throughout the body. The systemic effect ensures comprehensive coverage rather than localized action.

What side effects are possible with Japrolox?

Possible Side Effects and Safety Information

The safety profile of Loxoprofen Sodium, an NSAID, is structured around adverse reactions officially documented in regulatory labeling, such as that provided by the Pharmaceuticals and Medical Devices Agency (PMDA).

Adverse reactions are classified by frequency and grouped into affected physiological systems, known as System-Organ Classes.

Documented Adverse Reaction Scope

Category Examples (Common Reactions)
Gastrointestinal Disorders Nausea, vomiting, abdominal discomfort, diarrhea.
Hepatobiliary Disorders Elevated liver enzymes (AST, ALT).
Blood and Lymphatic Disorders Eosinophilia.

Serious Adverse Reactions

The label documents potentially life-threatening risks, consistent with the NSAID class, which are classified as serious adverse reactions regardless of their frequency. These include severe Gastrointestinal Lesions such as peptic ulceration, hemorrhage, and perforation. Serious systemic events, like Shock and Anaphylaxis, and severe Cutaneous Reactions (e.g., Stevens-Johnson Syndrome) are also documented. Cardiovascular warnings highlight the risk of serious thrombotic events, including myocardial infarction and stroke, which may increase with the duration of use.

Safety Constraints and Special Populations

Official labeling requires specific caution for certain groups. Older adults may face an increased risk of serious adverse reactions, especially those involving the gastrointestinal tract. The medication is contraindicated for individuals with a history of aspirin-induced asthma. Furthermore, the use of NSAIDs is generally avoided at 20 weeks or later in pregnancy due to potential fetal risks.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Loxoprofen Sodium (Japrolox) documents specific systemic manifestations following an overdose, necessitating immediate medical attention.

Documented Overdose Manifestations Overdose presentations may include Gastrointestinal effects such as Nausea, Vomiting, and Abdominal Pain. Severe Central Nervous System (CNS) disturbances are a primary concern, documented as Drowsiness, Dizziness, and potentially severe Disorders of Consciousness. Cardiovascular signs, including Tachycardia (increased heart rate) and Hypertension (elevated blood pressure), have also been reported.

Severe Outcomes and Required Actions Massive ingestion can lead to life-threatening outcomes, including Coma, Seizures, Metabolic Acidosis, and the complication of Acute Kidney Injury.

  • Urgent Medical Care: Individuals must seek immediate medical attention for any suspected overdose. Contact emergency services is required if severe CNS symptoms—such as loss of consciousness, confusion, or seizures—are observed.
  • Management Notes: Treatment is strictly symptomatic and supportive, as no specific antidote is known for this medicine. Procedures like Gastric Lavage or administration of Activated Charcoal may be considered by medical professionals. Close monitoring of renal function is necessary, particularly as slight renal impairment may be associated with delayed elimination of the active metabolite.

The regulatory documents emphasize that continuous hospital monitoring is essential when severe or life-threatening symptoms are present.

Therapeutic Uses of Japrolox

What Japrolox treats: main uses and benefits

Japrolox is generally used for symptomatic relief in situations involving certain distressing symptoms. Loxoprofen is indicated for relief of physical discomfort in conditions like rheumatoid arthritis, osteoarthritis, lumbago, periarthritis scapulohumeralis, and toothache. It is applied in contexts where supportive assistance for symptom management is needed to ease overall burden.

This medication is commonly used across conditions characterized by periods of heightened symptoms such as chronic joint diseases, and when acute, unstable symptom patterns arise from sudden events like physical trauma or postoperative pain. It helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations.

Key Therapeutic Applications

This medicine may be part of symptomatic management for chronic inflammatory joint disorders (e.g., rheumatoid arthritis and osteoarthritis), acute pain following physical trauma or surgical procedures, and episodic discomfort such as primary dysmenorrhea and fever related to acute upper respiratory inflammation.

“It is applied across domains where additional symptomatic support is needed to address discomfort and functional strain.”

Quick Fact: Relief for Pain and Inflammation

Japrolox assists with maintaining functional stability during periods of heightened musculoskeletal pain and supports general well-being during symptomatic phases.

Regulatory References

  1. PMDA Summary of Investigation Results

Eligibility and Restrictions for Use

Japrolox (Loxoprofen Sodium) eligibility is strictly determined by official regulatory criteria, centering on age, physiological status, and underlying health conditions.

The medicine is established for use in adult patients. However, use is formally not established in all pediatric populations, including infants, children, and adolescents. Elderly subjects require careful administration and close clinical monitoring.

Use is contraindicated in several groups due to severe health risks. These prohibitions include patients with severe cardiac function failure, severe renal impairment, severe hepatic function disorders, or severe blood disorders. It must also not be used by individuals with active peptic ulcers or a history of aspirin-induced asthma. Furthermore, Japrolox is strictly contraindicated during the third trimester of pregnancy.

Certain populations require cautionary use. This applies to patients with non-severe cardiac dysfunction or a history of non-severe hepatic or renal impairment. Similarly, patients with non-severe peptic ulcers, ulcerative colitis, or Crohn's disease should use the medicine under restriction. For women in the first and second trimesters of pregnancy, use is restricted and only permitted if the potential benefit outweighs the unestablished safety risk. Administration to nursing mothers should be avoided.

What should I know about interactions with other medicines?

This section details the officially documented interaction profile for Japrolox, grounded in authoritative government regulatory data, and focuses strictly on label-based constraints and consequences.

Contraindicated Combinations and Additive Risk

Co-administration with other non-steroidal anti-inflammatory drugs (NSAIDs) is generally recommended to be avoided. A specific pharmacodynamic interaction with Anticoagulants (e.g., Warfarin) and Anti-platelet Agents is documented due to the risk of increased hemorrhage and bleeding, resulting from Loxoprofen's effect on platelet function. Furthermore, the combination with New Quinolone Antibacterial Agents is restricted due to the potential for inducing convulsions.

Exposure-Modifying Interactions

Japrolox may interfere with the elimination of certain medicines, leading to increased blood concentrations and potential toxicity. This is a pharmacokinetic effect resulting from the decreased renal excretion of co-administered substances, including Lithium preparations and Methotrexate. The effects of Sulphonylurea Antihyperglycemic Drugs may also be increased due to protein binding displacement.

Pharmacodynamic Antagonism and Other Restrictions

Concomitant use with Antihypertensive Agents (e.g., ACE inhibitors, ARBs) or Diuretics may lead to a reduction in their therapeutic efficacy. Official regulatory text includes a specific substance restriction, advising against the consumption of alcohol before or after administration. The drug's use is also formally contraindicated in the third trimester of pregnancy due to the interaction-related risk concerning the fetal ductus arteriosus.

Mechanism of Action

Pro-drug Activation and Cyclooxygenase Inhibition

Japrolox operates through a characteristic sequence beginning with its role as a pro-drug. The inactive compound is rapidly metabolized into trans-OH loxoprofen, the active form. This metabolite acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). This initial molecular step is crucial as it suppresses the biosynthesis of downstream lipid mediators, specifically curtailing the production of Prostaglandins ( PGE2).

Regulation of Physiological Responses

The suppression of PGE2 dictates three key physiological adjustments: nociceptor sensitization, prostaglandin-mediated vascular changes, and central thermoregulation. The reduction in mediator concentration prevents the sensitization of peripheral pain receptors, resulting in the physiological consequence of anti-nociception. The same mechanism acts locally to restrict vasodilation, leading to the physiological consequence of reduced swelling. In the hypothalamus, the mechanism causes a resetting of the body's thermoregulatory set point, resulting in the physiological consequence of anti-pyresis.

Dosage and Administration Information

How to Use Japrolox

The usage of Loxoprofen Sodium (Japrolox) is guided by standardized instructions that establish the route, dosage limits, frequency, and specific administration conditions. These parameters define the conventional method of application in clinical practice.

Administration and Dosage Regimens

Japrolox is approved for oral administration as a tablet. The dosage strategy varies depending on whether the medicine is used for routine maintenance or acute, as-needed relief. Dosage may be adjusted according to a patient's age and the severity of their symptoms.

Usage Pattern Single Dose (Anhydrous Loxoprofen Na) Maximum Daily Dose
Routine Administration 60 mg 180 mg
As-Needed (p.r.n.) 60 mg to 120 mg 180 mg

Frequency and Timing Principles

For routine administration in chronic inflammatory conditions, the typical pattern is three times a day (TID). When used for acute conditions, such as fever, the tablet is administered as needed, but the frequency should not exceed twice a day for that specific context.

Standard administration protocols state that the medicine should be avoided on an empty stomach. Furthermore, if a scheduled dose is missed, the general procedure is to skip the dose if it is almost time for the next one, rather than taking two doses simultaneously.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Japrolox

The information below summarizes the clinical research and evidence base for Loxoprofen Sodium (Japrolox), drawing only from official and peer-reviewed sources. It focuses on how the medicine has been studied and what research describes, without providing any medical guidance or advice.

Evidence for Use in Chronic Musculoskeletal Conditions

This area of research was studied for conditions characterized by fluctuating or episodic manifestations, such as rheumatoid arthritis and osteoarthritis, as well as common conditions like lumbago and shoulder periarthritis.

Studies explored populations of adult patients with these chronic conditions, primarily utilizing short-term Randomized Controlled Trials (RCTs). Outcomes related to physical discomfort and scales that assess daily functioning or activity level were observed in these trials, which were designed to examine short-term symptom changes over defined time intervals. Studies report how symptoms evolved in the observed populations regarding measured changes in pain and functional scores across the groups.

Research provides insight into short-term changes during initial use, but there is limited information for long-term outcomes. This means long-term effects are not fully established, and results apply only to the populations studied, as much of the research pool was observed in specific regional populations.

Evidence for Use in Acute Pain Management

The evidence for this use is derived from short-term, double-blind, placebo-controlled trials that was studied for short-term symptom relief following events like physical trauma and surgical procedures (such as tooth extractions).

These trials included adults and examined outcomes describing episodic or acute changes, such as the intensity of pain and the use of additional pain relief medication. Research examined data show patterns related to changes in pain intensity. Studies report how symptoms evolved in the observed populations in terms of outcomes related to physical discomfort.

Follow-up durations were limited, often lasting only for a day or up to seven days. Research is not fully established regarding the medicine’s outcomes related to systemic or functional imbalance after the acute injury has passed. Data for certain groups remain insufficient, particularly for long-term functional outcomes.

Evidence for Symptomatic Relief of Episodic Pain and Fever

Research was evaluated in settings relevant in trials assessing short-term or episodic symptom patterns, such as primary dysmenorrhea and discomfort or fever related to acute upper respiratory inflammation.

Trials monitored outcomes linked to inflammatory or irritative states, including changes in body temperature and patient-reported pain severity during episodes where symptoms become more noticeable. Studies also explored patient-reported outcomes describing perceived discomfort. However, findings were mixed regarding the medicine's impact on the overall duration of certain illnesses, with research primarily focusing on symptom control.

Evidence is limited on how the medicine was observed in patients with pre-existing health issues or comorbidities. For conditions like primary dysmenorrhea, research examined short-term symptom changes, but there are no data to fully describe use over multiple successive cycles.

Long-Term Data and Follow-up in Clinical Research

The majority of evidence is derived from short-term trials designed to assess initial symptom response. Post-marketing surveillance and observational data, which were observed in daily-life functioning, contribute to the broader evidence landscape by tracking patient experiences over longer durations.

These real-world data sources generally provide context but not individual predictions and research does not determine whether an individual will respond similarly to the group patterns. There is limited information for long-term outcomes regarding the medicine's sustained use for chronic conditions.

Evidence in Specific Patient Populations

Clinical research was studied for Loxoprofen Sodium primarily in adult populations. Data for certain groups remain insufficient or non-existent in the core evidence base.

Comparative evidence is lacking or limited for populations such as children and adolescents. Studies monitored older adults in some chronic musculoskeletal condition research, but generally, the subgroup findings are uncertain. The evidence base does not fully characterize the use of the medicine in pregnant populations or patients with certain serious, complex medical histories.

What is Still Uncertain About Japrolox Research

The evidence highlights what is known — and what is still uncertain. Key limitations include that follow-up durations were limited across many core trials, meaning the long-term effects are not fully established.

Evidence quality varies across studies, and the fact that a large portion of the research was observed in specific regional populations means results apply only to the populations studied. Data for certain groups remain insufficient, particularly for long-term use in patients with chronic underlying conditions.

Frequently Asked Questions (FAQ)

Common questions about Japrolox (FAQ)

Q: What are the most common side effects of Japrolox that people report online?

Official safety information lists common documented reactions consistent with its classification as an NSAID. These frequently reported issues affect the gastrointestinal system, and may include nausea, vomiting, or diarrhea. Other common documented effects include headache, minor skin reactions, or drowsiness.

Q: Is there any risk when taking Japrolox with common pain relievers like ibuprofen?

Regulatory text advises against combining Japrolox with other non-steroidal anti-inflammatory drugs (NSAIDs). This official recommendation is based on the documented potential for increased adverse effects when combining NSAIDs.

Q: Is Japrolox safe for older adults or elderly patients?

Official prescribing information describes that use in older adults requires careful administration and close clinical monitoring. This is due to a documented increased risk of serious adverse reactions in this population, particularly those involving the gastrointestinal tract.

Q: What happens if I accidentally take two doses of Japrolox close together?

Taking more than the prescribed amount, or in quick succession, increases the risk of serious adverse reactions. A higher dose may lead to severe gastrointestinal damage or potential impairment of liver or kidney function. Taking more than the recommended amount is not advised.

Q: What are the most common reasons a doctor might prescribe Japrolox?

The medicine is generally approved for addressing pain, inflammation, and fever associated with various conditions. These commonly include rheumatoid arthritis, osteoarthritis, low back pain (lumbago), and acute pain experienced after trauma or surgical procedures.

Q: Is Japrolox the same type of drug as [Specific Competitor Drug]?

Japrolox is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) that belongs to the propionic acid derivative subgroup within this pharmaceutical class.

Q: Can Japrolox cause trouble sleeping or insomnia?

Regulatory documents note that drowsiness is a documented common side effect of Japrolox. As drowsiness is a central nervous system effect, it is listed in the safety information.

Q: Does Japrolox affect your mood or make you feel dizzy?

Dizziness is listed in official safety information as a documented common side effect of Japrolox. However, specific adverse reactions related to changes in mood are not commonly documented in core regulatory texts.

Q: Is it common for people to gain weight while taking Japrolox?

While weight gain itself is not commonly listed, official safety documentation notes edema as a less common side effect. Edema is defined as swelling due to fluid retention in the body.

Q: Why is Japrolox not recommended for people under 18?

Official prescribing information states that the safety of Japrolox has not been established in children and adolescents. This is due to limited clinical experience and insufficient data collected from these pediatric populations.

Q: Is Japrolox known to cause any long-term effects on the liver?

Official safety information lists elevated liver enzymes (AST and ALT) as a documented adverse reaction. This documented adverse reaction is an indication of effects on liver function.

Q: Can Japrolox be taken before surgery?

Japrolox possesses anti-platelet effects, which can interfere with blood clotting. Consistent with the NSAID drug class, it is formally contraindicated in the peri-operative period of coronary artery bypass graft (CABG) surgery.

Q: What is the maximum amount of time official sources recommend taking Japrolox?

Official guidelines recommend using all NSAIDs, including Japrolox, for the shortest duration necessary. This is due to risks associated with long-term use, such as cardiovascular or gastrointestinal complications.

Q: Does Japrolox interact with diabetes medication like metformin?

Official interaction summaries document that Japrolox may increase the effects of Sulphonylurea Antihyperglycemic Drugs. This is due to the drug’s potential to affect how other substances are processed in the body.

Q: What is the difference between the immediate-release and extended-release versions of Japrolox?

Japrolox (Loxoprofen Sodium) is documented in official sources as being available primarily in an oral tablet form for systemic administration.

Q: What are the documented symptoms of a Japrolox overdose?

Symptoms associated with a high dose are documented in medical literature and may involve disorders of consciousness, gastrointestinal symptoms, and potential impairment of liver or kidney function. These are documented symptoms associated with high-dose ingestion.

Q: What should I know about taking Japrolox if I have a heart condition?

Japrolox is formally contraindicated for people with severe cardiac function failure. It also carries a class warning regarding the risk of serious cardiovascular thrombotic events (such as heart attack or stroke), which is a risk that may increase with the duration of use.

Q: Is Japrolox considered a maintenance drug or a short-course treatment?

Japrolox is approved for both routine administration (maintenance) in chronic conditions and for acute, as-needed relief. However, official guidelines stress that use should be limited to the shortest duration necessary.

Q: How does Japrolox affect my body compared to a placebo?

Clinical trials for acute pain management are documented as being double-blind and placebo-controlled. Research has examined outcomes related to changes in pain intensity and functional scores in populations receiving the medicine versus those receiving a placebo.

Q: Is the benefit of Japrolox supported by clinical trials?

The benefit of Japrolox is supported by clinical research, including randomized controlled trials. These studies have examined outcomes related to the reduction of physical discomfort and changes in various symptom scores.

Q: Can a person with mild kidney problems use Japrolox?

Official eligibility criteria list severe renal impairment as a formal contraindication. Patients with non-severe renal impairment are included in the cautionary use population, meaning use is subject to restriction and careful monitoring.

How should Japrolox be stored and disposed of?

Japrolox (Loxoprofen Sodium) must be stored and disposed of strictly according to the official regulatory instructions to preserve its quality and ensure safety.

Storage Scope Regulatory Requirements
Temperature Limit Store in a cool place at a temperature not exceeding 30 C; generally classified as room temperature.
Protection Must be kept away from direct sunlight, heat, and moisture in a light-proof, tightly-sealed container.
Container Rule Do not transfer the tablets from the original packaging.
Child Safety Mandatory to keep out of the reach of children.
Stability/Use The product must be used before the expiration date on the label; discard the remainder after the treatment course.
Disposal Disposal of unused product and packaging must be conducted in accordance with local, regional, and national regulations.

These official statements define that the medicine requires environmental control, container integrity, and careful handling. The primary storage constraints are temperature limits and protection from light and moisture. Disposal must follow authorized waste management procedures rather than general household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Japrolox found in:

A-Z Index: